Paracetamol in Patent Ductus Arteriosus Treatment: Efficacious and Safe?

Area of Science:

• Neonatalogy
• Pharmacology
• Pediatric Cardiology

Background:

• Patent Ductus Arteriosus (PDA) is a significant concern in preterm infants, potentially leading to serious complications.
• Current management strategies for PDA, particularly the timing and methods of intervention, remain subjects of debate.
• Hemodynamically significant PDA is the primary target for intervention, with medical therapy as the first-line approach.

Purpose of the Study:

• To review the efficacy and safety of paracetamol (acetaminophen) as a treatment for PDA in preterm infants.
• To compare paracetamol with traditional nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen for PDA closure.
• To assess the potential of paracetamol as a safer alternative in PDA management.

Main Methods:

• Systematic review of existing studies on paracetamol use for PDA closure.
• Analysis of clinical data regarding the effectiveness of paracetamol in achieving ductal closure.
• Evaluation of reported side effects, including nephrotoxicity and liver enzyme levels.

Main Results:

• Paracetamol demonstrates efficacy in closing the Ductus Arteriosus (DA) in preterm infants.
• Reported side effects of paracetamol are generally mild and transient, primarily involving slight elevations in liver enzymes.
• Paracetamol appears to have a lower toxicity profile compared to ibuprofen, particularly concerning nephrotoxicity.

Conclusions:

• Paracetamol is a viable and potentially safer alternative to NSAIDs for treating PDA in preterm infants.
• Further comprehensive studies are essential to validate the long-term safety and outcomes of paracetamol therapy.
• More research is required before paracetamol can be considered the first-choice medication for PDA treatment.